U.S. FDA Accepts For Priority Review The sBLA For Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
“Trodelvy has already changed the treatment landscape in second-line metastatic triple-negative breast cancer and pre-treated metastatic urothelial cancer, and today’s news marks our third supplemental application acceptance within the last two years,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology. “People with pre-treated HR+/HER2- metastatic breast cancer who have progressed on endocrine-based therapies and chemotherapy have limited treatment options, and we look forward to working with the FDA to potentially make Trodelvy available to patients who need it most.”
Share:
More News
“The completion of the UDENYCA divestiture in April positions us to focus on our innovative oncology portfolio,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “This includes maximizing LOQTORZI revenues, advancing our novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026, and progressing label expanding
“GSK plc with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug, an anti-TIGIT monoclonal antibody. The decision is based on new interim analyses from the phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which did not meet the established efficacy criteria for
“We are truly disappointed by the results from GALAXIES Lung-201,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. “Following the analysis of the TIGIT data generated to-date with GSK, we have made the mutual decision to discontinue development of all ongoing TIGIT studies. We are grateful to
“The FDA’s decision to grant Fast Track designation to ZL-1310 highlights the significant need for expanded treatment options for patients with SCLC and represents an important step in our efforts to advance a novel therapeutic option as quickly as possible,” said Rafael G. Amado, M.D., President, Head of Global Research
